Companies: 10,795·Total market cap: $144.5T
Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

DNTHNASDAQHealthcare● Active
$80.51
$-3.62(-4.30%)
Market Cap$3.4B
P/E Ratio
52W High$96.5
52W Low$16.64
Overview

Dianthus Therapeutics, Inc. (DNTH) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · DNTH · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.11dnth eps ttm · dnth earnings per shareEarnings history
PE Ratio (TTM)dnth pe ratio ttm · dnth price to earningsPE Ratio deep dive
Revenue (TTM)$1.3Mdnth revenue ttm · dnth annual revenueFull revenue history
Dividend YieldNo Dividenddoes dnth pay dividends · dnth dividend yieldDividend history
Shares Outstanding37.8Mdnth shares outstanding · dnth floatShares outstanding history
Next EarningsAug 6, 2026Est.dnth earnings date · dnth next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$2.0M▼ 67.35% YoY
202320242025
dianthus therapeutics, inc. revenue · dnth revenue 2025
FY 2025Net Income-$162.3M▼ 91.05% YoY
202320242025
dianthus therapeutics, inc. net income · dnth profit 2025
FY 2025EPS$-4.20▼ 64.71% YoY
202320242025
dnth eps · dianthus therapeutics, inc. earnings per share 2025
TTM:Revenue: $1.3MNet Income: -$11.3MEPS: $-0.11View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy10 analystsis dnth a buy · dnth analyst rating
Strong Buy
1
Buy
9
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$55.00Low
$80.51Current
$111.91Avg Target39.00% upside
$145.00High
dnth price target · dnth 12 month forecast

Total: 10 · Buy rate: 100.0%

The DNTH analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $111.91, representing +39.00% upside from the current price of $80.51.

Stock Performance

Full History
1D-4.30%
1W-2.42%
1M-7.15%
3M+23.48%
YTD+95.37%
1Y+342.61%
5Y-57.28%

About Dianthus Therapeutics, Inc.

CEOMarino Garcia
IPO DateJun 21, 2018
Employees78
CountryUS

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammator…

what is dianthus therapeutics, inc. · dnth stock overview · dianthus therapeutics, inc. company profile · who is dianthus therapeutics, inc. ceo · dnth NASDAQ · dianthus therapeutics, inc. headquarters · dianthus therapeutics, inc. business segments

About Stock Overview & Key Data

Dianthus Therapeutics, Inc. (DNTH) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 21, 2018. As of the latest trading session, DNTH stock price is $80.51, with a market capitalization of $3.4B. The stock has returned +342.61% over the past 12 months and +95.37% year-to-date.

According to 10 Wall Street analysts, the consensus rating for Dianthus Therapeutics, Inc. stock is Buy, with an average 12-month price target of $111.91. In fiscal year 2025, Dianthus Therapeutics, Inc. reported revenue of $2.0M and net income of -$162.3M. For detailed data — including Dianthus Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Dianthus Therapeutics, Inc. (DNTH) stock price is $80.51. The stock is traded on NASDAQ under the ticker symbol DNTH. The 52-week range is $16.64 – $96.50.

DNTH stock priceDNTH quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice